biostudies-literatureRichardson MHealth Research Council of New Zealand1331-1342https://www.ebi.ac.uk/biostudies/studies/S-EPMC12273618biostudies-literatureUnknown40(7)<h4>Background</h4>A previous case series showed that Nocebo Hypothesis Cognitive Behavioral Therapy (NH-CBT) is a promising treatment for Functional Neurological Symptom Disorder (FNSD).<h4>Objectives</h4>To further evaluate the potential efficacy of NH-CBT in participants with FNSD (motor type).<h4>Methods</h4>This phase IIb pilot, randomized, parallel group trial compared the efficacy of NH-CBT (n = 20) with an active control condition (n = 19). Self-report scales of motor and other physical symptoms, psychological variables, and blinded assessor ratings of participants' mobility were administered at baseline, and at 8- and 16-week follow-ups. The primary outcome and endpoint of this trial was the Physical Functioning scale of the Short Form-36 Health Questionnaire (SF-36 PF) at the endMovement disorders : official journal of the Movement Disorder SocietyNocebo Hypothesis Cognitive Behavioral Therapy for Functional Neurological Symptom Disorder (Motor Type): A Pilot Randomized Controlled Trial.PMC1227361820/045Wong DRichardson MKleinstauber MfalseNocebo Hypothesis Cognitive Behavioral Therapy for Functional Neurological Symptom Disorder (Motor Type): A Pilot Randomized Controlled Trial.<h4>Background</h4>A previous case series showed that Nocebo Hypothesis Cognitive Behavioral Therapy (NH-CBT) is a promising treatment for Functional Neurological Symptom Disorder (FNSD).<h4>Objectives</h4>To further evaluate the potential efficacy of NH-CBT in participants with FNSD (motor type).<h4>Methods</h4>This phase IIb pilot, randomized, parallel group trial compared the efficacy of NH-CBT (n = 20) with an active control condition (n = 19). Self-report scales of motor and other physical symptoms, psychological variables, and blinded assessor ratings of participants' mobility were administered at baseline, and at 8- and 16-week follow-ups. The primary outcome and endpoint of this trial was the Physical Functioning scale of the Short Form-36 Health Questionnaire (SF-36 PF) at the end2025-01-01T00:00:00Z2025 Jul2026-03-18T13:54:39.577Z2025-08-21T09:52:58.091ZS-EPMC122736184035367510.1002/mds.30195